IP Library Granted Patent US 7,524,877
Granted Patent B2
US 7,524,877 · App. 11/371,689 · Granted Apr 28, 2009

Compounds for use in weight loss and appetite suppression in humans

Assignee: Seroctin Research & Technology, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,877
App. No.
11/371,689
Granted
Apr 28, 2009
Kind
B2
Abstract

Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen or another oxygen containing group, and a C 1 -C 4 alkoxy group, obtainable from monocotyledonous plants, or by chemical synthesis, have been found to act as weight loss agents, appetite suppressants mood enhancers and adjunctive therapy for arthritis, sleep apnea, fibromyalgia, diabetes and hyperglycemia. Additional chemical compounds of the present invention may include benzoxazinoids-cyclic hydroxyamic acids, lactams, and corresponding gluxosides, which may serve as precursors to phenolic compounds. The phenolic compounds and precursors of phenolic compounds of the present invention, at concentrations suitable for human therapeutic use, may be obtained from monocotyledonous plants such as corn in their early growth states which are timely harvested for optimum yield.

Claims (30)

1. A process for promoting weight loss and/or suppressing appetite in a mammal by the administration of an amount of 6-methoxy-2,3-benzoxazolinone defined as:

or a pharmaceutically acceptable salt thereof,

said amount of 6-methoxy-2,3-benzoxazolinone being sufficient to promote weight loss and/or suppress appetite in said mammal,

wherein said 6-methoxy-2,3-benzoxazolinone is obtained from at least one of (i) a leafy and/or immature plant part of one or more monocotyledonous plants, (ii) animal tissue or (iii) chemical synthesis.

2. A process as defined in claim 1 , wherein said administered amount of said 6-methoxy-2,3-benzoxazolinone comprises a daily dosage of between about 5 mcg and about 60 mg.

3. A process as defined in claim 1 , wherein said administered amount of said 6-methoxy-2,3-benzoxazolinone comprises a daily dosage of about 15 mg.

4. A process as defined in claim 1 , wherein said 6-methoxy-2,3-benzoxazolinone is obtained at least in part from a leafy and/or immature plant part one or more monocotyledonous plants selected from the group consisting of corn, wheat, barley, rye, oats, rice, sorghum, millet, bamboo, Job's Tears, barley-like grasses, and wild grasses.

5. A process as defined in claim 4 , wherein said leafy and/or immature plant part is dried.

6. A process as defined in claim 5 , wherein said leafy and/or immature plant part is dried at a temperature in the range of between about 40° C. and about 45° C.

7. A process as defined in claim 5 , wherein said leafy and/or immature plant part contains phenols in total amounts greater than 17.0 mg/gm (dry weight).

8. A process as defined in claim 5 , wherein said leafy and/or immature plant part contains combined amounts of 4-hydroxycinnamic acid and 4-hydroxy-3-methoxycinnamic acid totaling no more than 1.5 mg/gm (dry weight).

9. A process as defined in claim 5 , wherein said leafy and/or immature plant part is obtained from an immature com plant, Zea mays.

10. A process as defined in claim 9 , wherein said immature corn plant has been grown to a height between about 45 centimeters and about 122 centimeters.

11. A process as defined in claim 9 , wherein said immature corn plant has been grown to a height that does not exceed between about 30 centimeters and about 45 centimeters.

12. A process as defined in claim 9 , wherein said immature corn plant has been grown for less than ten weeks after planting.

13. A process as defined in claim 1 , wherein said 6-methoxy-2,3-benzoxazolinone is administered in a manner selected from the group consisting of:

(1) oral administration; (2) intranasal administration; (3) transmucosal administration; (4) parenteral injection; (5) implant for sustained release; and (6) transdermal patch.

14. A process as defined in claim 4 , wherein a portion of said amount of 6-methoxy-2,3-benzoxazolinone is obtained by at least one of chemical synthesis or is isolated, extracted and/or purified from a natural plant or animal source.

15. A process as defined in claim 1 , wherein said 6-methoxy-2,3-benzoxazolinone is obtained from one or more monocotyledonous plants and standardized with synthesized 6-methoxy-2,3-benzoxazolinone.

16. A process as defined in claim 2 , said composition being administered to a human, said amount of 6-methoxy-2,3-benzoxazolinone further enhancing mood and/or treating at least one of fibromyalgia, sleep disorder, hyperglycemia, arthritis, physical or psychological condition caused by stress, or substance addiction in said human.

17. A process for promoting weight loss and/or suppressing appetite and/or enhancing mood and/or treating at least one of fibromyalgia, sleep disorder, hyperglycemia, arthritis, physical or psychological condition caused by stress, or substance addiction in a human by the administration of an amount of 6-methoxy-2,3-benzoxazolinone defined as:

or a pharmaceutically acceptable salt thereof,

said amount of said 6-methoxy-2,3-benzoxazolinone comprising a daily dosage of between about 5 mcg and about 60 mg to promote weight loss and/or suppress appetite and/or enhance mood and/or treat at least one of fibromyalgia, sleep disorder, hyperglycemia, arthritis, physical or psychological condition caused by stress, or substance addiction in said human,

wherein said 6-methoxy-2,3-benzoxazolinone is isolated, extracted and/or purified from at least one of (i) a leafy and/or immature plant part of one or more monocotyledonous plants, (ii) animal tissue or (iii) chemical synthesis.

18. A process as defined in claim 17 , wherein said 6-methoxy-2,3-benzoxazolinone is isolated, extracted and/or purified at least in part from a leafy and/or immature plant part of one or more monocotyledonous plants selected from the group consisting of corn, wheat, barley, rye, oats, rice, sorghum, millet, bamboo, Job's Tears, barley-like grasses, and wild grasses.

19. A process as defined in claim 17 , the process comprising enhancing mood and/or treating a mental or mood disorder in a human caused by stress.

20. A process for promoting weight loss and/or suppressing appetite and/or enhancing mood and/or treating physical or psychological effects of stress in a human by the administration of an amount of 6-methoxy-2,3-benzoxazolinone defined as:

or a pharmaceutically acceptable salt thereof,

said amount of said 6-methoxy-2,3-benzoxazolinone comprising a daily dosage of between about 5 mcg and about 60 mg to promote weight loss and/or suppress appetite and/or enhance mood and/or treat physical or psychological effects of stress in said human,

wherein said 6-methoxy-2,3-benzoxazolinone is isolated, extracted and/or purified from a leafy and/or immature plant part of one or more monocotyledonous plants and/or is prepared by chemical synthesis.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2020
From: SEROCTIN RESEARCH AND TECHNOLOGY, INC.
To: SAVANNA HEALTH LLC
Reel/Frame 054408/0237 →
RELEASE OF SECURITY INTEREST Recorded Aug 15, 2011
From: FORSBERG GROUP, LLC
To: SEROCTIN RESEARCH AND TECHNOLOGY
Reel/Frame 026751/0291 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR FROM SEROCTIN RESEASRCH AND TECHNOLOGY, INC. TO SEROCTIN RESEARCH AND TECHNOLOGY, INC. PREVIOUSLY RECORDED ON REEL 026427 FRAME 0173. ASSIGNOR(S) HEREBY CONFIRMS THE FORSBERG GROUP, LLC HAS A LIEN ON SRT'S INTEREST IN THE LISTED ISSUED PATENTS.. Recorded Jun 17, 2011
From: SEROCTIN RESEARCH AND TECHNOLOGY, INC.
To: FORSBERG GROUP, LLC
Reel/Frame 026460/0645 →
LIEN Recorded Jun 10, 2011
From: SEROCTIN RESEASRCH AND TECHNOLOGY, INC.
To: FORSBERG GROUP, LLC
Reel/Frame 026427/0173 →
Continuity (2)
Division 1071823200 · Nov 20, 2003
Related Publication 20060148795A1 · Jul 6, 2006